Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Safety and Tolerability of TAR-200 in Subjects With Muscle-Invasive Bladder Cancer Who Are Unfit for Radical Cystectomy

Bladder

The purpose of this study is to determine if TAR-200, an investigational drug-delivery system, is safe and tolerable in patients with muscle-invasive bladder cancer (MIBC) who are unfit for radical cystectomy (RC) during an 84-day induction period comprised of four consecutive 21-day dosing cycles.
Bladder
I
Keegan, Kirk
NCT03404791
VICCURO17103

Percutaneous Transhepatic Biliary Drainage or Endoscopic Retrograde Cholangiography in Treating Participants with Suspected Malignant Bile Duct Obstruction

Liver

This phase III trial studies how well percutaneous transhepatic biliary drainage works versus endoscopic retrograde cholangiography in treating participants with suspected cancerous (malignant) bile duct obstruction. Percutaneous transhepatic biliary drainage is a procedure that uses x-rays to guide a needle through the skin into the bile duct to allow for drainage of the blockage through external tubes. Endoscopic retrograde cholangiography is a procedure that combines the use of a lighted camera that goes down through the mouth and x-rays to diagnose and treat certain problems of the biliary ductal system, and permits drainage of the blockage through internal stents. It is not yet known whether percutaneous transhepatic biliary drainage or endoscopic retrograde cholangiography is most effective in treating participants with suspected malignant bile duct obstruction.
Liver
N/A
Yachimski, Patrick
NCT03172832
VICCGI17104

Chemotherapy Levels in the Eyes of Patients with Retinoblastoma

Retinoblastoma (Pediatrics)

Retinoblastoma (Pediatrics)
N/A
Daniels, Anthony
VICCREACH17106

Atezolizumab and Cobimetinib or Idasanutlin in Treating Participants with Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer

Breast

This phase I / II trial studies the side effects and best dose of idasanutlin when given together with atezolizumab, and to see how well atezolizumab and cobimetinib or idasanutlin work in treating participants with stage IV estrogen-receptor positive (ER+) breast cancer, or ER+ breast cancer that has come back (recurrent) and cannot be removed by surgery (unresectable). Monoclonal antibodies, such as atezolizumab, may interfere with the ability of tumor cells to grow and spread. Cobimetinib and idasanutlin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab with cobimetinib or atezolizumab with idasanutlin may work better in treating participants with estrogen-receptor positive breast cancer.
Breast
I/II
Mayer, Ingrid
NCT03566485
VICCBRE17107

Developing Evidence-Based Criteria for Initiating Treatment for Neurofibromatosis Type 1 Associated Optic Pathway Glioma

Multiple Cancer Types

Neuro-Oncology, Pediatrics
N/A
Esbenshade, Adam
VICCPED17108

The Collection of Blood Samples from Patients with NF1 for Research Purposes

Multiple Cancer Types

Neuro-Oncology, Pediatrics
N/A
Esbenshade, Adam
VICCPED17109

Study of GBR 1342, a CD38 / CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

Multiple Myeloma

The purpose of this study is to determine the safety profile and maximum tolerable dose (MTD) of single-agent GBR 1342 in subjects with multiple myeloma who have received prior therapies.
Multiple Myeloma
I
Cornell, Robert
NCT03309111
VICCHEMP17111

Olaparib and Ramucirumab in Treating Patients with Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

Gastric/Gastroesophageal

This pilot phase I / II trial studies the side effects and best dose of olaparib when given together with ramucirumab and how well they work in treating patients with gastric or gastroesophageal junction cancer that has spread to other places in the body, has come back, or cannot be removed by surgery. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as ramucirumab , may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving olaparib and ramucirumab may work better in treating patients with gastric or gastroesophageal junction cancer compared to ramucirumab and paclitaxel (a chemotherapy drug) or ramucirumab alone.
Gastric/Gastroesophageal
I/II
Goff, Laura
NCT03008278
VICCGI17112

Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1)

Multiple Cancer Types

GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody intended for the treatment of cancers of different histology. This is a first-time-in-human (FTIH), open-label, multicenter study designed to investigate the safety, pharmacology, and preliminary antitumor activity in subjects with advanced or recurrent solid tumors with the aim to establish recommended dose(s) of GSK3359609 for further exploration as monotherapy and in combination with pembrolizumab or chemotherapy regimens. The study is comprised of two primary parts, each composed of two phases: Part 1: GSK3359609 monotherapy with Part 1A as dose escalation phase and Part 1B as cohort expansion phase; Part 2: GSK3359609 combination therapy with Part 2A pembrolizumab or GSK3174998 combination dose escalation phase and Part 2B expansion phase with pembrolizumab. Part 2A GSK3359609 combinations with chemotherapy will only consist of safety run-in cohorts. Each part and phase of the study includes a screening period, a treatment period, and a follow-up period. The primary objective of the study is to determine the safety, tolerability, maximum tolerated dose or the maximum administered dose of GSK3359609 alone or in combination.
Lung, Non Small Cell, Phase I
I
Horn, Leora
NCT02723955
VICCTHOP17113

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: